The MyoVista® Wavelet ECG (wavECG™) Device includes breakthrough technology that is designed to assist in the early detection of heart disease. HeartSciences breakthrough innovation in electrocardiography adds new features that assist in screening for the detection of cardiac dysfunction.
MyoVista wavECG Device is an innovative advancement in low-cost electrocardiographic testing and benefits from more than 10 years of research and development. It uses advanced signal processing that features the use of wavelet mathematics. Wavelet mathematics are used in many different industries today since new potentially valuable information is provided from spectral analysis of a signal. MyoVista wavECG Device produces a sensitivity of 78% and a specificity of 71%* for the detection of diastolic dysfunction. During a recent clinical trial MyoVista Technology produced a sensitivity of 88% and a specificity of 87%* using machine learning analysis which indicates even greater future capability for the detection of diastolic dysfunction.
• Data on file at HeartSciences